Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vitro |
RAD51 is an essential part of the DNA repair pathway for homologous recombination and is overexpressed in cancers that are resistant to drugs, such as aggressive triple-negative breast cancer (TNBC)[1].
RAD51-IN-1 (10 μM) reduces the ratio of RAD51 positive cells/cH2AX positive cells in MDA-MB-231 cell exposure to 6 Gy irradiation[1]. RAD51-IN-1 (10 μM) significantly reduces the formation of RAD51 foci induced by DNA damage when exposed to 6 Gy of radiation[1]. |
---|---|
References |
Molecular Formula |
C22H16CLN3O
|
---|---|
Molecular Weight |
373.834943771362
|
Exact Mass |
373.1
|
Elemental Analysis |
C, 70.68; H, 4.31; Cl, 9.48; N, 11.24; O, 4.28
|
CAS # |
2101739-18-6
|
PubChem CID |
53245568
|
Appearance |
Yellow to orange solid powder
|
LogP |
4
|
Hydrogen Bond Donor Count |
0
|
Hydrogen Bond Acceptor Count |
3
|
Rotatable Bond Count |
4
|
Heavy Atom Count |
27
|
Complexity |
582
|
Defined Atom Stereocenter Count |
0
|
SMILES |
C1=CC=C2C(=C1)C(=O)N(C(=N2)/C=C/C3=CN=CC=C3)CC4=CC=C(C=C4)Cl
|
InChi Key |
AQNDWTVLZSMOQU-FMIVXFBMSA-N
|
InChi Code |
InChI=1S/C22H16ClN3O/c23-18-10-7-17(8-11-18)15-26-21(12-9-16-4-3-13-24-14-16)25-20-6-2-1-5-19(20)22(26)27/h1-14H,15H2/b12-9+
|
Chemical Name |
3-[(4-chlorophenyl)methyl]-2-[(E)-2-pyridin-3-ylethenyl]quinazolin-4-one
|
Synonyms |
RAD51-IN 1; RAD51-IN1; RAD51-IN-1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~62.5 mg/mL (~167.2 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6750 mL | 13.3751 mL | 26.7501 mL | |
5 mM | 0.5350 mL | 2.6750 mL | 5.3500 mL | |
10 mM | 0.2675 mL | 1.3375 mL | 2.6750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.